News

Law

Asset Management

Investment Banking

Wealth

Hedge Funds

People

Newsletters

Events

Lists

Allergan's bitter pill for Morgan Stanley

Allergan, which is fending off a $53 billion takeover bid by Valeant, released emails sent by senior Morgan Stanley bankers appearing to denigrate Valeant and its business strategy

The mudslinging between Allergan and Valeant got more intense on Monday. But it was Morgan Stanley bankers who found themselves caught in the crossfire.

Allergan, which is fending off a $53 billion takeover bid by Valeant, released emails sent by senior Morgan Stanley bankers appearing to denigrate Valeant and its business strategy.

WSJ Logo